The Need-to-Know This Morning

• monte‍ Rosa Therapeutics and Novartis have entered into a research collaboration focused on developing novel treatments for autoimmune diseases.the collaboration will leverage Monte rosa’s protein degrader technology, a promising approach to targeting disease-causing ‍proteins.
• Aizer pharma (formerly Atyr pharma) announced that its experimental drug, efzofitimod,⁢ did not demonstrate a statistically significant ⁢reduction in the use of oral steroids compared to ‍placebo in a Phase 3 clinical trial. The ⁢trial evaluated efzofitimod in patients ⁣wiht pulmonary sarcoidosis,a⁤ chronic inflammatory ‍lung condition. This setback casts doubt on the drug’s⁢ future growth for ⁢this indication.
  ⁣ ‍

FDA Retreats From Expert Drug Panels

⁣ The Food and Drug Administration (FDA) is reportedly scaling back its long-standing practice⁤ of convening ⁢autonomous advisory committees to ⁢review new drug applications. According to reporting from ⁢STAT ⁢News, ⁤this shift, occurring under recent leadership appointments, raises concerns about transparency‍ and the⁤ potential for diminished ⁤external scrutiny of drug approval decisions.

⁢ For decades, these advisory committees – comprised of external experts in relevant fields – have provided ‍independent assessments of a drug’s ‍safety and efficacy before the FDA⁤ makes a final decision. Reducing reliance on these panels could lead to faster approvals, but critics ⁢worry it may compromise the rigor of the‍ review process and potentially prioritize speed over safety. The move echoes ‍concerns raised during the Trump administration regarding the FDA’s independence.
⁢

⁤ The FDA has not yet ⁤publicly released detailed guidance on the extent of these changes, but sources within the⁤ agency‍ suggest a⁤ more⁣ selective approach to convening advisory committees, reserving them primarily for drugs with particularly complex⁣ or controversial ⁣profiles.
⁣